Atossa_Therapeutics_logo-min.png
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 09, 2023 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
April 27, 2023 09:15 ET | Atossa Therapeutics, Inc.
Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
March 22, 2023 16:05 ET | Atossa Therapeutics, Inc.
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
March 21, 2023 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa to Present at the Sidoti Small-Cap Virtual Conference
March 15, 2023 09:25 ET | Atossa Therapeutics, Inc.
SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
February 23, 2023 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen
February 13, 2023 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Issues Letter to Shareholders
January 25, 2023 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
December 07, 2022 08:00 ET | Atossa Therapeutics, Inc.
SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 07, 2022 16:00 ET | Atossa Therapeutics, Inc.
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on...